{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"The Healthy Enterprise","title":"The Broken Pipeline: Rethinking Drug Development","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/67101978\"></iframe>","width":"100%","height":180,"duration":2811,"description":"Kayla Ellsworth explores why nearly 90% of drug candidates fail and how New Approach Methodologies (NAMs) are transforming drug development. She explains how technologies like AI, omics, advanced in vitro models, and microphysiological systems better replicate human biology, improving research while reducing reliance on animal testing. The conversation also highlights the importance of innovation, women in leadership, and emerging technologies such as brain-on-a-chip that are shaping the future of healthcare.\nChapters:\n00:00 The Drug Development Crisis\n09:08 Introducing New Approach Methodologies (NAMS)\n17:53 Exploring NAMS: In Silico to Microphysiological Systems\n25:19 Dynamic Microphysiological Systems\n26:39 Evidence of Effectiveness in Drug Development\n28:48 Speeding Up Drug Development Processes\n30:42 Integrating New Approaches in Drug Development\n32:17 The Future of Animal Testing\n34:21 Women in Leadership and Industry\n39:43 Role of Speccro in Drug Development\n42:35 Innovations on the Horizon\nGuest Information:Guest's Name: Kayla Ellsworth\nGuest's Title/Position: Scientific Operations Coordinator\nLinkedIn: https://www.linkedin.com/in/kayla-ellsworth-18a2841a0/\nCompany / Affiliation: SPECCRO https://speccro.com/\nGuest's Bio: Kayla Ellsworth is the Scientific Operations Coordinator  at SPECCRO, where she helps connect biotechnology and pharmaceutical companies with innovative preclinical research solutions. Passionate about advancing human-relevant drug development, she works with industry leaders to promote emerging technologies such as organ-on-chip models, iPSCs, and New Approach Methodologies (NAMs). Through her work, Kayla helps foster collaborations that are shaping the future of safer, more predictive drug discovery.\nTakeaways:The drug development process is failing with a 90% failure rate.NAMS offer innovative solutions to improve drug development.Animal testing is outdated and needs to be replaced.In silico methods use computational modeling for...","thumbnail_url":"https://img.transistorcdn.com/WKku9MQ84q-0q9Awqd5xdS4eoTolo1ocic6_1x8xlF0/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9mMjI4/MDliNWYyM2MxYWFi/NTkwZmIwNzJkYjk2/YjliMy5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}